WuXi Biologics Cayman Inc. will sell a vaccine facility in Ireland to Merck & Co. for about $500 million as the Chinese ...

WuXi Biologics’ move to sell the facility could strengthen the company’s cash flow and margins as it navigates global ...

China's WuXi Biologics said on Monday it will sell its vaccine facility in Ireland to U.S. drugmaker Merck & Co for about ...

The Financial Times had reported in October, citing people familiar with the matter, that WuXi and WuXi AppTec are planning ...

China's WuXi Biologics said on Monday it will sell its vaccine facility in Ireland to U.S. drugmaker Merck & Co for about ...

Medical-device maker Stryker on Monday agreed to acquire Inari Medical , which makes devices that treat patients with venous ...

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

Shares of Merck & Co. Inc. MRK slumped 0.31% to $99.17 Thursday, on what proved to be an all-around dismal trading session ...

Merck (MRK) ended the recent trading session at $99.72, demonstrating a +0.59% swing from the preceding day's closing price. The stock outperformed the S&P 500, which registered a daily gain of 0.55%.

The acquisition from Wuxi Biologics, the embattled CDMO named in the BIOSECURE Act, marks another expansion of Merck’s ...

Merck, a leading science and technology company, announced the closing of the transaction to acquire HUB Organoids Holding ...

In Ireland, WuXi Biologics has sold a new vaccines plant to Merck & Co. for €500 million ($521 million). The New Jersey ...